Further improvement in IVF outcome may need more than consistency in ovarian stimulation.
It is agreed that reliability of hormonal products, starting with recombinant technology, has improved uniformity of ovarian response to a specified dosage, and that this has resulted in better pregnancy rates. Nevertheless, IVF cycle cancellation rate has not experienced a substantial decline in the last 5-10 years. We feel that further improvement will be more likely to be achieved once we gain better understanding of factors intrinsic to oocyte biology, such as oocyte ageing and oocyte depletion.
Balmaceda
Jose P
JP
Reproductive Medicine Unit, Clinica Las Condes, Lo Fontecilla 441, Santiago, Chile. jbalmace@clinicalascondes.cl
Schwarze
Juan-Enrique
JE
D005260:Female; D005307:Fertilization in Vitro / Q000592:standards*; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use; D015292:Glycoprotein Hormones, alpha Subunit / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D010062:Ovulation Induction / Q000592:standards*; D011247:Pregnancy; D018873:Pregnancy Rate
D043373:Follicle Stimulating Hormone, Human; D015292:Glycoprotein Hormones, alpha Subunit; D005640:Follicle Stimulating Hormone